1. Home
  2. Analysis
  3. Ceftriaxone-sodium
  4. Mobic

Ceftriaxone sodium and Mobic drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ceftriaxone sodium and Mobic. Common interactions include carbohydrate antigen 125 increased among females and chronic kidney disease among males.

The phase IV clinical study analyzes what interactions people who take Ceftriaxone sodium and Mobic have. It is created by eHealthMe based on reports of 9 people who take Ceftriaxone sodium and Mobic from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 18, 2023

9 people who take Ceftriaxone sodium and Mobic together, and have interactions are studied.

What is Ceftriaxone sodium?

Ceftriaxone sodium has active ingredients of ceftriaxone sodium. eHealthMe is studying from 4,952 Ceftriaxone sodium users for its effectiveness, alternative drugs and more.

What is Mobic?

Mobic has active ingredients of meloxicam. It is often used in arthritis. eHealthMe is studying from 25,688 Mobic users for its effectiveness, alternative drugs and more.

Number of Ceftriaxone sodium and Mobic reports submitted per year:

Ceftriaxone sodium and Mobic drug interactions.

Common Ceftriaxone Sodium and Mobic drug interactions by gender *:

female:

  1. Carbohydrate antigen 125 increased
  2. Chest injury
  3. Colitis
  4. Constipation
  5. Diarrhoea
  6. Dizziness
  7. Fall
  8. Haemorrhage
  9. Insomnia
  10. Memory impairment

male:

  1. Chronic kidney disease
  2. Renal failure

Common Ceftriaxone Sodium and Mobic drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Chronic kidney disease
  2. Renal failure

60+:

  1. Cardiac failure
  2. Myelodysplastic syndrome
  3. Colitis
  4. Constipation
  5. Diarrhoea
  6. Dizziness
  7. Fall
  8. Haemorrhage
  9. Insomnia
  10. Memory impairment

* Approximation only. Some reports may have incomplete information.

Do you take Ceftriaxone sodium and Mobic?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Ceftriaxone sodium and Mobic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ceftriaxone sodium side effects:

Browse all side effects of Ceftriaxone sodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Mobic side effects:

Browse all side effects of Mobic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ceftriaxone sodium interactions:

Browse all interactions between Ceftriaxone sodium and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Mobic interactions:

Browse all interactions between Mobic and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ceftriaxone sodium and meloxicam (the active ingredients of Ceftriaxone sodium and Mobic, respectively), and Ceftriaxone sodium and Mobic (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Ceftriaxone sodium and Mobic.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.